PA-WESTINGHOUSE-ELECTRIC
22.2.2024 10:01:28 CET | Business Wire | Press release
Westinghouse organized the 5th annual VVER Fuel Forum in Bratislava with representatives from six utilities. The forum, hosted by Slovenské elektrárne, provided the opportunity to share experiences and best practices with VVER-1000 and VVER-440 fuel deployment in operating reactors.
Westinghouse offered detailed briefings on fuel licensing, NOVA E-6 design enhancements, fabrication plant upgrades, delivery and operations.
As the leader of the European Union-funded APIS project (Accelerated Program for Implementation of secure VVER fuel Supply), Westinghouse also presented additional information on next-generation fuel design development and a harmonized approach for VVER fuel licensing.
“We are pleased to host so many colleagues in Bratislava to discuss the critical topic of fuel diversification,” said Branislav Strýček, Chairman of the Board of the Board of Directors and General Director of Slovenské elektrárne. “We are currently going through the preparation of the documentation in Slovakia for new VVER-440 fuel and expect to finish the licensing process by 2026-2027. We are looking forward to achieving diversification of fuel sources as we expand the lifetime operations of our nuclear plants.”
“In Ukraine, we started the licensing process for the Westinghouse VVER-440 fuel in 2022 and, thanks to great cooperation, we successfully completed it within 1.5 years. We received the first fuel load for Rivne unit 2 last September, ahead of the originally planned schedule. Our two units will be operating later this year with the new fuel, which has been performing well after six months," said Olexandr Depenchuk, Director for Nuclear and Radiation Safety of Energoatom. “The joint efforts of Energoatom and Westinghouse have enabled us to end our dependence on Russian fuel.”
“We recommend expediting the ongoing fuel diversification efforts in the context of the REPowerEU Plan launched in May 2022 and the global energy disruption caused by Russia’s invasion of Ukraine,” said Stefano Ciccarello, Acting Director General of the Euratom Supply Agency.
In Finland, Fortum is pursuing mechanical operating experiences with the new fuel type, after a test assembly manufactured by Westinghouse was loaded into the Loviisa-2 reactor last year. “The changes done in the design of the VVER-440 fuel we originally used in Loviisa in the early 2000s improved the fuel behavior and performance. We are currently reviewing the licensing and manufacturing documentation of the first new fuel deliveries and expect this work to be ready this summer,” said Iiro-Ville Lehtinen, Fortum Project Manager.
“Westinghouse will deliver the first batch of VVER-440 fuel assemblies to the Dukovany nuclear power plant at the end of this year. The deliveries for Temelín will follow a few months after Dukovany, as mutually agreed based on the refueling schedule,” said Rostislav Štaubr, Head of Nuclear Fuel Procurement of CEZ.
“We really appreciate our collaboration with Westinghouse,” said Svilena Nikolova, Head of Legal and Commercial Department of Kozloduy Nuclear Power Plant. “The diversification that has been obtained in terms of nuclear fuel supply is of great importance for the power plant. As Kozloduy celebrates its 50th anniversary this year, we will also receive the first load of new VVER-1000 fuel from Westinghouse for our unit 5.”
“We are delighted to share the achievements of this key program to ensure energy security and supply diversification for our customers in the region,” said Tarik Choho, Westinghouse President of Nuclear Fuel. “There were many great achievements in the past years and still a lot of work ahead of us. As the only European VVER fuel manufacturer, we are committed to delivering what is required by our customers.”
Westinghouse is a leading supplier of nuclear fuel, providing a uniquely diversified portfolio in the industry across nuclear reactor types, including PWR, BWR, AGR and VVER. Through our world-class manufacturing facilities in Sweden, the U.K. and the U.S., we focus on delivering innovative fuel technologies to meet our customers’ needs for lower fuel cycle costs, increased operational flexibility and efficiency, diversity of supply and accident-tolerant products. Learn more about our advanced fuel capabilities and how they relate to different reactors around the world: Westinghouse Nuclear > Nuclear Fuel.
Westinghouse Electric Company is shaping the future of carbon-free energy by providing safe, innovative nuclear technologies to utilities globally. Westinghouse supplied the world’s first commercial pressurized water reactor in 1957 and the company’s technology is the basis for nearly one-half of the world's operating nuclear plants. Over 135 years of innovation make Westinghouse the preferred partner for advanced technologies covering the complete nuclear energy life cycle. For more information, visit www.westinghousenuclear.com and follow us on Facebook, LinkedIn and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222283969/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
